Because BMD undergoes extensive changes after menopause ( Sowers et al. 1992 ), we tested for effect modification by menopause status at the time of DXA scan (premenopause vs. perimenopause/menopause). In addition, to examine whether associations differed based on timing of TCDD exposure, we tested for effect modification by exposure occurring before or after peak bone mass [defined for each participant as 2 years after her self-reported age at menarche ( Theintz et al. 1992 )] and by exposure before or after 5 years of age ( Alaluusua et al. 2004 ). We also assessed statistical interactions between log 10 TCDD and current thyroid-stimulating hormone and BMI, examining each variable in continuous and categorical/binary forms; no interactions were significant for any of the outcomes (with significant interactions defined as p < for a cross-product interaction term).
9. Determining Quantity Based on Doses, Pills, or Capsules .—If the number of doses, pills, or capsules but not the weight of the controlled substance is known, multiply the number of doses, pills, or capsules by the typical weight per dose in the table below to estimate the total weight of the controlled substance ( . , 100 doses of Mescaline at 500 milligrams per dose = 50 grams of mescaline). The Typical Weight Per Unit Table, prepared from information provided by the Drug Enforcement Administration, displays the typical weight per dose, pill, or capsule for certain controlled substances. Do not use this table if any more reliable estimate of the total weight is available from case-specific information.